## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.4% below STRENGTH zone (3.0-6.0%); PEG 35.42 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.60)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. What Do Analysts Think About Baxter International Inc. (BAX)?**
- Source: Insider Monkey | 20260102T144826 | Neutral | Relevance: 100%
- Wells Fargo analyst Larry Biegelsen reiterated a Hold rating on Baxter International Inc. (NYSE:BAX) with a $19.00 price target based on positive data regarding smart infusion pump integration. Conversely, Morgan Stanley analyst Patrick Wood cut the price target on BAX to $15 from $19, maintaining an Underweight rating. The article suggests that while BAX has potential, other AI stocks may offer higher returns with limited downside risk.

**2. Who Owns Baxter International? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260101T130755 | Neutral | Relevance: 100%
- This article details the top institutional shareholders of Baxter International (NYSE: BAX) and recent insider trading activities. It highlights that while large institutions like Vanguard and Dodge & Cox lead its shareholder base, there's a mix of accumulation and trimming, indicating varied confidence in the company's recovery. Insider activity largely consists of small selling transactions and equity awards, suggesting limited strong conviction signals from company leadership.

**3. The Truth About Becton Dickinson & Co (BDX): Quiet Giant Or Sleeper Stock You’re Sleeping On?**
- Source: AD HOC NEWS | 20260102T000748 | Neutral | Relevance: 64%
- This article examines Becton Dickinson & Co (BDX), a healthcare giant behind essential medical supplies, arguing it's a solid long-term investment despite lacking "meme stock" appeal. It highlights BDX's stable business model rooted in consistent demand for indispensable hospital equipment and its steady compounding growth. The piece concludes that BDX is a "COP" for serious, diversified portfolios due to its foundational role in healthcare.

**4. The Truth About Becton Dickinson & Co (BDX): Quiet Giant Or Sleeper Stock You’re Sleeping On?**
- Source: AD HOC NEWS | 20260102T000147 | Neutral | Relevance: 61%
- Becton Dickinson & Co (BDX) is a healthcare giant that, while not considered "flashy" or a "meme stock," plays a crucial role in modern healthcare by providing essential medical equipment. This article examines why BDX, despite its low profile, is a preferred stock for serious investors due to its stable business model, consistent demand, and steady growth. It compares BDX to competitors like Baxter International and concludes that it is a solid long-term investment for a diversified portfolio.

**5. The Truth About Steris plc: Quiet Healthcare Giant or Next Big Stock Glow-Up?**
- Source: AD HOC NEWS | 20260101T070843 | Neutral | Relevance: 58%
- Steris plc is presented as an unassuming but critical player in the healthcare sector, specializing in sterilization and infection control. The article explores whether this "boring-but-profitable" stock is a worthwhile long-term investment, highlighting its stable business model, consistent financial performance, and strong market positioning compared to competitors. It suggests Steris is a "cop" for serious, risk-aware investors seeking stable healthcare exposure rather than volatile, short-term gains.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.17M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.4x requires aggressive growth execution.
2. Elevated short interest (9.8%): bears positioning against stock.
3. Long-term trend broken: trading 23.6% below SMA200.

### Catalysts

- Momentum building: MRS_10 improving +2.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 35.42 signals overvaluation risk, limited margin of safety. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.42 |
| Forward P/E | 8.5 |
| Current P/E | 8.3 |
| YoY Growth | -2.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.2% to 2.4% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.6pp (needs >3.0% for momentum thesis). MRS_5 at 1.7% confirms short-term momentum alignment. Below SMA200 (0.76x), long-term trend not supportive. RSI neutral at 56. OFD pattern: +STL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.44% (CS: 80) | Neutral |
| RSI_14 | 56.3 | Neutral |
| MACD Histogram | 0.09 | Bullish |
| vs SMA20 | 1.029x | Above |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 0.764x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $19.50
- **Stop Loss:** $18.60 (4.6% risk)
- **Target:** $20.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1600
- **Position Value:** $31,200.00
- **Portfolio %:** 31.20%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*